Skip to main content
Fig. 2 | Lipids in Health and Disease

Fig. 2

From: Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

Fig. 2

Reduction of medium VLDL particles correlated with baseline lipoprotein(a) concentrations. Every circle represents the posterior mean reduction of medium VLDL particle concentration and the posterior mean of baseline lipoprotein(a) in a patient treated with evolocumab. The vertical and horizontal bar represents the 95% credible interval. The blue dashed line represented the average percentage (50%) change in medium VLDL particle after evolocumab treatment

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X